Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05217407

Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia

A Prospective Clinical Registry Study of Genetic Profiling and Targeted Therapies in Patients With Rare Cancers in ASIA

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,000 (estimated)
Sponsor
National Cancer Center, Japan · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a registry study that aims to collect patients' data with advanced-stage rare cancer in Asia-Pacific region. Data includes clinical information, details of treatment, prognosis, pathological diagnosis and genetic biomarkers by next-generation sequencing. The relationship between cancer types and prognosis, the effect of treatments, and the cancer type-specific incidence of genomic alterations will be investigated to discover more specific and effective treatment.

Conditions

Interventions

TypeNameDescription
OTHERGenomic sequenceGenomic sequence

Timeline

Start date
2021-11-30
Primary completion
2027-03-31
Completion
2030-03-31
First posted
2022-02-01
Last updated
2024-03-22

Locations

18 sites across 7 countries: Japan, Malaysia, Philippines, South Korea, Taiwan, Thailand, Vietnam

Source: ClinicalTrials.gov record NCT05217407. Inclusion in this directory is not an endorsement.

Marker Assisted Selective ThErapy in Rare Cancers: Knowledge Database Establishing registrY Asia (NCT05217407) · Clinical Trials Directory